Vertex Pharmaceuticals Inc.

VRTX · Nasdaq · ·

Vergelijken

US$ 538,53-0,8%slot 13 nov

Cijfers tot en met 30 september 2026, uit de 10-Q ingediend op 3 november 2026

1W: -1,6%
1M: +8,0%

Aandeel Vertex Pharmaceuticals Inc. (VRTX) — is dit een goed bedrijf? — InspectStocks

Vertex Pharmaceuticals Inc.

VRTX · Nasdaq · ·

Vergelijken

US$ 538,53-0,8%slot 13 nov

Cijfers tot en met 30 september 2026, uit de 10-Q ingediend op 3 november 2026

1W: -1,6%
1M: +8,0%

Just reported

Q3 2026 results

From Vertex Pharmaceuticals's results release of 2 november 2026; its quarterly report has since been filed.

Revenue
Actual
US$ 3,44B
+12% y/y
+3,2% q/q
Guided
—
No guide given
EPS, GAAP
Actual
US$ 2,56
-39% y/y
-41% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
US$ 712,9M
-40% y/y
-43% q/q
Guided
—
No guide given

Company outlook

Full year 2026

RevenueUS$ 13,15B – US$ 13,25B+10,0% y/y Raised +0,4%

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Vertex Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Samengesteld
Biotech
Door InspectStocks · 19 companies
Drug developers with approved medicines, built mainly on biologic and genetic science.
Koers, 1 jaar
+26,8%
Omzet, 1 jaar
+12,9%
+13
A 8B 4C 5D 1F 1

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

All 355 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Hoe het geld verdient

TRIKAFTA/KAFTRIO sales75%
ALYFTREK sales17%
KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI sales4%
CASGEVY sales2%
JOURNAVX sales2%

De omzetaandelen zijn schattingen voor quarter ended June 30, 2026, geen cijfers uit een ingediend rapport.

Concurreert met

Wat het verkoopt5

ALYFTREK
A once-daily combination medicine that improves the function of the faulty protein that causes cystic fibrosis.
TRIKAFTA/KAFTRIO
A combination medicine that improves the function of the faulty protein that causes cystic fibrosis. TRIKAFTA and KAFTRIO are brand names used in different markets.
KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI
Other medicines for cystic fibrosis that improve the function of the protein involved in the disease.

Nog 2 tonen

CASGEVY
A gene-editing treatment for severe sickle cell disease and transfusion-dependent beta thalassemia. A patient's blood-forming cells are collected, edited at a manufacturing facility, and returned for infusion.
JOURNAVX
An oral, non-opioid medicine for moderate-to-severe acute pain in adults.

Wie het koopt5

Specialty pharmacies and specialist distributors buy Vertex medicines and resell them to patients, pharmacies, health care providers, hospitals, or treatment centers.
Major wholesalers in the United States buy Vertex medicines for resale through pharmacies and health care providers.
Outside the United States, distributors, retail pharmacies, hospitals, and clinics buy or distribute medicines; some hospitals and clinics are government-owned or supported.

Nog 2 tonen

Authorized treatment centers can receive CASGEVY directly from Vertex in some markets.
Government health programs and commercial insurers decide whether to cover medicines and reimburse purchases.

Waar het op steunt, en wat het kan breken

Waar het bedrijf van afhangt

1The business depends substantially on cystic fibrosis medicines; sales therefore depend on continued patient use, access, and the medicines' ability to compete with other treatments.
2Vertex relies on outside manufacturers and suppliers for much of its commercial and clinical supply. CASGEVY also requires coordinated cell collection, editing, shipping, and treatment-center infusion.
3Sales depend on government programs and commercial insurers covering medicines and agreeing to reimbursement terms. The company also pays royalties on certain cystic fibrosis medicines and shares CASGEVY profits with CRISPR Therapeutics.

Wat er mis kan gaan

1The company identifies its cystic fibrosis medicines as a substantial source of business dependence. Competing treatments, changes in patient use, or loss of patent protection could reduce sales.
2Vertex's future products depend on clinical trials showing acceptable safety and benefit and on regulators approving them. A delay or failure in programs such as povetacicept, inaxaplin, or zimislecel could limit its ability to add new medicines.
3The company relies on complex supply chains, outside manufacturers, and treatment-center coordination, particularly for cell and gene therapies. Manufacturing or distribution problems could delay or interrupt supply.

Volledige jaarrekening →

Over Vertex Pharmaceuticals Inc.

Vertex discovers, tests, manufactures, and sells prescription medicines. Its approved medicines treat cystic fibrosis, severe sickle cell disease, transfusion-dependent beta thalassemia, and moderate-to-severe acute pain; it is also testing treatments for kidney disease, type 1 diabetes, and other conditions. It sells mainly through specialty pharmacies, distributors, and wholesalers, with some gene therapy supplied directly to treatment centers.

Hoofdkantoor: Boston, Massachusetts
Opgericht in: 1989
Medewerkers: 6,400 (December 31, 2025, high)
Genoteerd aan: NASDAQ
Einde boekjaar: December 31

Gebouwd uit de eigen deponeringen van Vertex Pharmaceuticals Inc. bij de Amerikaanse toezichthouder Securities and Exchange Commission (SEC). De cijfers zijn zoals gerapporteerd, met de historie per aandeel herrekend naar de huidige aandelenbasis. Dit beschrijft een bedrijf — het is geen beleggingsadvies en geen aanbeveling om iets te kopen of te verkopen.

Just reported